Cargando…
Dopamine Agonists for Pituitary Adenomas
Dopamine agonists (DA) are well established as first-line therapy for prolactinomas. These tumors express high levels of dopamine 2 receptors (D2R), leading to the strong efficacy of DA in reducing tumor size and hormonal secretion. Other pituitary tumor subtypes express D2R to varying degrees, lead...
Autores principales: | Cooper, Odelia, Greenman, Yona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110840/ https://www.ncbi.nlm.nih.gov/pubmed/30186234 http://dx.doi.org/10.3389/fendo.2018.00469 |
Ejemplares similares
-
Editorial: Targeted Therapy for Pituitary Adenomas
por: Araki, Takako, et al.
Publicado: (2019) -
FRI305 Impulse Control Disorders In Patients With Prolactinomas And Non-Functioning Pituitary Adenomas Treated With Dopamine Agonists
por: Kolitz, Tamara, et al.
Publicado: (2023) -
Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review
por: Cooper, Odelia, et al.
Publicado: (2021) -
Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas
por: Hinojosa-Amaya, José Miguel, et al.
Publicado: (2020) -
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
por: Pivonello, Claudia, et al.
Publicado: (2022)